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ABSTRACT
Cancer stem-like cells (SLC) resist conventional therapies, necessitating searches for SLC-speciﬁc
targets. We established that cyclo-oxygenase(COX)-2 expression promotes human breast cancer
progression by activation of the prostaglandin(PG)E-2 receptor EP4. Present study revealed that
COX-2 induces SLCs by EP4-mediated NOTCH/WNT signaling. Ectopic COX-2 over-expression in
MCF-7 and SKBR-3 cell lines resulted in: increased migration/invasion/proliferation, epithelialmesenchymal transition (EMT), elevated SLCs (spheroid formation), increased ALDH activity and
colocalization of COX-2 and SLC markers (ALDH1A, CD44, b-Catenin, NANOG, OCT3/4, SOX-2) in
spheroids. These changes were reversed with COX-2-inhibitor or EP4-antagonist (EP4A), indicating dependence on COX-2/EP4 activities. COX-2 over-expression or EP4-agonist treatments of
COX-2-low cells caused up-regulation of NOTCH/WNT genes, blocked with PI3K/AKT inhibitors.
NOTCH/WNT inhibitors also blocked COX-2/EP4 induced SLC induction. Microarray analysis
showed up-regulation of numerous SLC-regulatory and EMT-associated genes. MCF-7-COX-2 cells
showed increased mammary tumorigenicity and spontaneous multiorgan metastases in NOD/
SCID/IL-2Rc-null mice for successive generations with limiting cell inocula. These tumors showed
up-regulation of VEGF-A/C/D, Vimentin and phospho-AKT, down-regulation of E-Cadherin and
enrichment of SLC marker positive and spheroid forming cells. MCF-7-COX-2 cells also showed
increased lung colonization in NOD/SCID/GUSB-null mice, an effect reversed with EP4knockdown or EP4A treatment of the MCF-7-COX-2 cells. COX-2/EP4/ALDH1A mRNA expression
in human breast cancer tissues were highly correlated with one other, more marked in progressive stage of disease. In situ immunostaining of human breast tumor tissues revealed colocalization of SLC markers with COX-2, supporting COX-2 inducing SLCs. High COX-2/EP4 mRNA
expression was linked with reduced survival. Thus, EP4 represents a novel SLC-ablative target in
human breast cancer. STEM CELLS 2016;34:2290–2305

SIGNIFICANCE STATEMENT
This study presents novel mechanistic findings that cyclo-oxygenase (COX)-2 induces stem-like
cells (SLC) in human breast cancer by activation of the prostaglandin E-2 receptor EP4 leading
to up-regulation of NOTCH/WNT via PI3K/AKT signaling pathways. COX-2 induced SLC properties
resulting from EP4/PI3K/AKT activation were confirmed with mammary site transplants and
lung colonization of COX-2 over-expressing cells in immune deficient mice, showing multi-organ
metastasis. In human breast cancer tissues, (a) SLC markers were localized mostly to COX-21
cells; (b) COX-2/EP4/ALDH1A mRNAs were highly correlated with one another; and (c) high
COX-2/EP4 expression were associated with reduced survival. We suggest that EP4 antagonist,
which spare cardio-protective prostanoids, are better suited than COX-2 inhibitors for SLCreduction in this disease.

INTRODUCTION
Breast cancer strikes one in eight women in
North America and accounts for the second
highest cause of cancer-related mortality in
females, mostly ascribable to metastatic disease [1]. Traditional treatment modalities complemented by target-oriented therapies
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including HER-2-blockade have recently prolonged the survival. However, many patients
still remain unresponsive or develop resistance
to the target-oriented drugs, indicating the
need for personalized therapeutics [2].
A tumor cell subpopulation known as
“stem-like cells” (SLC)s is thought to play a
major role in tumor progression, metastasis,
C AlphaMed Press 2016
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and recurrence after traditional therapy [3]. In support, several studies have shown a positive association of embryonic
stem (ES) cell markers such as OCT4, NANOG, and SOX-2 with
cancer metastasis [4, 5]. Whether arising from mutations in
tissue-speciﬁc stem/progenitor cells or from dedifferentiation
of breast cancer cells, SLCs are characterized by the expression of certain markers. Breast cancer-associated SLCs have
been reported as CD44 high, CD24 low and ALDH positive [6].
In addition, proteins such as Snail, ZEB1, and Twist, involved
in epithelial-mesenchymal transition (EMT), have also been
linked with SLC phenotype [7–9].
Cyclo-oxygenase (COX)-2, an inﬂammation-associated
enzyme, plays a key role in tumor initiation in tissues subjected to chronic inﬂammation [10, 11]. COX-2 over-expression
is both a signature as well as a driver of tumor progression
and metastasis in a variety of epithelial cancers including
breast, and COX-2 inhibitors have shown chemo-preventive
and therapeutic effects [12]. COX-2 expression, found in 40%50% of primary human breast cancers, is a marker for
increased morbidity and poor survival [13]. Our studies in
murine and human breast cancer models established that elevated COX-2 expression by breast cancer cells promotes tumor
progression via multiple mechanisms: inactivation of host antitumor immune cells [14], enhancement of cancer cell migration and invasiveness [15, 16], promotion of tumor-associated
angiogenesis [15], and lymphangiogenesis resulting from upregulation VEGF-C/-D [5, 17, 18], induction of SLC and elevation of an oncogenic microRNA-526b [19].
PGE2, the major product of the COX-2 activation cascade
can bind to four G protein coupled receptors (EP1-EP4) having
distinct signaling capabilities [20]. Most of the abovementioned COX-2 mediated events promoting breast cancer
progression was due to activation of the PGE2 receptor EP4
on tumor and host cells by endogenous PGE2 [5, 17, 18].
While Gs coupled EP2 and EP4 receptors share signaling via
the cAMP/PKA pathway, EP4 also signals through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway [21, 22]. This differential signaling mechanism utilized by the EP4 receptor
protects cells from apoptosis, making EP4 antagonists (EP4A)
attractive alternatives to COX-2 inhibitors. Furthermore,
thrombo-embolic side effects of COX-2 inhibitors [23, 24] can
be avoided with EP4A since they do not inhibit cardioprotective prostanoids such as PGI2 [25]. We validated this
contention in a syngeneic mouse breast cancer model, in
which an EP4A at nontoxic doses were as effective as COX-2
inhibitors in exerting antitumor, antimetastatic, and SLCablative effects [5]. In the present study, we test the roles of
EP4 and its putative signaling pathways in SLC induction in
human breast cancer.
NOTCH and WNT signaling pathways, active during embryonic development, are also aberrantly activated during tumor
progression. Both NOTCH [26, 27] and WNT [28, 29] pathways
promote metastatic phenotypes in breast cancer cells. WNT/
b-catenin inhibition was shown to be SLC-reductive in breast
cancer [30]. PGE2, the major bioactive product of the COX-2
cascade, can activate components of the WNT signaling system [31]. However, COX-2/EP4 stimulation of WNT and NOTCH
signaling pathways in breast cancer has not been
documented.
While HER-2 is a major determinant of breast cancer progression, in murine models many HER-2 actions were COX-2
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mediated [32, 33]. We established that lymphangiogenic functions of HER-2 in human breast cancer are also COX-2
dependent [34]. In the present study, we asked whether COX2 or EP4 activation stimulates SLCs in both HER-2- and HER21 breast cancer cells by up-regulating NOTCH and WNT. We
herein demonstrate that COX-2 increases breast cancer SLCs
via EP4/PI3K-dependent induction of NOTCH/WNT signaling.
In human breast cancer tissues, we found that SLC markers
were localized mostly to COX-21 cells and COX-2/EP4/SLC
mRNAs were highly correlated with one another. Finally, high
COX-2/EP4 mRNAs were associated with reduced survival.
These studies establish the roles of COX-2/EP4 in SLC induction via PI3K/AKT/WNT/NOTCH pathways and further endorse
EP4 as a therapeutic target in human breast cancer.

MATERIALS

AND

METHODS

Ethics Statements
The human breast cancer and the adjacent noncancerous tissues used in this study were obtained from the Ontario Institute for Cancer Research (OICR) repository (Ontario Tumor
Bank, Toronto, CA) based on approval by their Ethics Board.
Use of mice was approved by the Animal Use Subcommittee
of this University of Western Ontario, according to the guidelines of the Canadian Council on Animal Care.

Cell Lines and Culture Conditions
Human breast cancer cell lines (MCF-7, SKBR-3, MDA-MB-468,
MDA-MB-231, Hs578T, and T47D) were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA) and
maintained according to ATCC protocol. MCF10A (COX-2, ER,
HER-2-) mammary epithelial cell line is a kind gift of Dr.
Moshmi Bhattacharya, University of Western Ontario. MCF-7
(COX-2-low, ER1, HER22, nonmetastatic) and SKBR-3
(COX22, ER2, HER21, weakly metastatic) cells were transfected with 2 mg of either pCMV-IRES2-EGFP-vector (Mock) or
pCMV-IRES2-EGFP-COX-2 expression plasmids (kind gift of Dr.
Michael Archer, University of Toronto) using the Amaxa Cell
Line Nucleofector Kit V (Lonza, Walkersville, MD) and the P020 or E-009 program for MCF-7 cells or SKBR-3 cells respectively, according to the manufacturer’s protocol. MCF-7-COX-2
and SKBR3-COX-2 and their respective mock cell lines were
maintained in regular media with GeneticinV (GIBCO, ON, CA)
at 500 lg/ml. We knocked-down EP4 (using same protocol) in
MCF-7-COX-2 cells using shRNA plasmids (cat#sc-40173-SH)
from Santa Cruz, Dallas, TX and stable cell lines named MCF7-COX-2-Mock and MCF-7-COX-2-EP4KD, were maintained in
regular media with Puromycin selection (300 ng/ml).
R

Drugs and Reagents
All in vitro concentrations of drugs were chosen as reported
earlier [5, 19]. NS-398 (COX-2 inhibitor, 20 lM), 10 lM each
of PGE2 (nonselective EP ligand) and PGE1OH (EP4 agonist)
were purchased from Cayman Chemical (Ann Arbor, MI).
ONO-AE3-208 (selective EP4 antagonist, 5 lM) was a gift of
ONO Pharmaceuticals, Osaka, Japan. PI3K inhibitors (10 lM
each) Wortmannin (WM) and LY-204002 (LY) were purchased
from Sigma-Aldreich (St. Louis, MO). DMSO (solvent) served
as control. We used WNT inhibitor rhDkk-1 (5 and 10 lM)
from R&D Systems, Minneapolis, MN and NOTCH inhibitor
C AlphaMed Press 2016
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DAPT (50 and 100 ng) from Sigma-Aldreich, 0.3% BSA in PBS
and DMSO served as vehicle control, respectively.

Real-Time PCR
We used RNeasy Kit (Qiagen, ON, CA) for RNA extraction and
cDNA was synthesized with High Capacity Reverse Transcription Kit (Applied Biosystems, Foster City, CA). To quantify COX2 (PTGS2), EP4 (PTGER4), E-Cadherin (CDH1), Vimentin (VIM),
TWIST1, SNAI1, ZEB1, N-Cadherin (CDH2), NOTCH (1-3), HES1,
HES6, AXIN1, AXIN2, c-MYC, Cyc-D1 (CCND1) and b-actin
(ACTB) genes, we used human quantitative TaqMan Gene
Expression probes from Applied Biosystems. Negative DCt values reﬂect higher mRNA expression in tissue samples. We
also conducted semi-quantitative RT-PCR as described previously [17] for VEGF-A/C/D, EPs and GAPDH, a primer list given
in Supporting Information Table 1.

Protein Detection and Measurement with Western
Blots
Protein (15-20 mg) was separated on 10% SDS-PAGE gel to
immuno-blot and quantify VEGF-A (sc-507), VEGF-C (sc-1881),
VEGF-D (sc-13085), COX-2 (sc-1747), using antibodies (1:500
dilutions) from Santa Cruz Biotechnology, Dallas, TX. Monoclonal GAPDH antibody (MAB374) was from Millipore, Billerica,
MA. Antibodies to ERK1/2 and phospho-ERK1/2 (9102 and
9101S), AKT, phospho-AKT-Ser473 (9272, 9271), E-Cadherin
(3195), Vimentin (5741) (used at 1: 1:500 to 1:1,000 dilutions)
were purchased from Cell Signaling, Danvers, MA. IRDye-800
conjugated antirabbit IgG, antigoat IgG and Alexa 680 conjugated antimouse IgG were used as secondary antibodies, as
appropriate (LI-COR, Lincoln, NE).

Migration, Invasion, and Proliferation Assays
For migration assays, 6 3 104 cells in 300 ml basal media
were added to the upper chamber of transwells including a
multiporous polycarbonate membrane (8 mm pore size) insert
Tewksbury, and placed in a 24-well plate (Corning Costar Corporation, Cambridge, MA). For invasion assays, cell inserts
were coated with Matrigel (1:100 in basal media; BD Biosciences, Mississauga, ON, CA). The lower chamber contained 700
ml of either serum-free media or 2% FBS-supplemented
media. Cells completing migration at 24 hours or invasion at
48 hours at 378C were quantiﬁed as reported earlier [15, 16,
35]. BrdU ELISA (Roche Applied Science, Indianapolis, IN) was
used to measure proliferation of MCF-7 and MCF-7-derived
cell lines at 6 hours, and SKBR-3 and SKBR-3-derived cell lines
at 8 hours [35].

Spheroid Formation
Cells were plated on ultra-low attachment plates (Corning
Costar Corporation, Cambridge, MA) at dilution of 1 cell/100
ll or 2 3 104 cells/2ml, as previously described [5, 19, 36].
Spheroids were harvested and their RNA extracted to conduct
real-time qPCR for target gene expression. Images of spheroid
were captured under a light microscope and the number and
perimeter of spheroids calculated using ImageJ (National Institutes of Health, Bethesda, MD).

Targeting EP4 to Abrogate Breast Cancer Stem Cells

NANOG, b-Catenin, with antibodies (1:300 dilution) from BD
biosciences, and staining conducted as reported previously
[5].

Fluorescence-Activated Cell Sorting
Breast cancer SLCs have been reported to be ALDH-high/
CD44 1 CD242 [2, 37]. We used ALDEFLUOR assay kit (StemCell Technologies, BC, Canada), followed by staining for CD44PE-Cy7 (560533) and CD24-PE (560991) conjugated antibodies
(BD Biosciences, San Jose, CA). Cells were concurrently
labeled with 7-aminoactinomycin (7-AAD, #560253) to test
viability and ﬂuorescently conjugated IgG isotype was applied
as negative controls (BD Biosciences). While staining for ALDH
activity alone, we used top 20% as ALDHhigh and bottom 20%
as ALDHlow [37]. To identify the CD44 1 CD242 subset, sorting
for ALDHhigh was set at top 10%, and ALDHlow at bottom 10%.
All markers were examined in monolayer and spheroid dissociated cells. Cell purity for each sorted population was 98%99%.

Microarray
We conducted gene microarrays (quadruplicate measurements) comparing mRNA expression changes between MCF-7COX-2 and Mock-transfected control cells, using Affymetrix
Genechip Micro-Array 1.0 as per manufacturer’s protocol.
ANOVA with a nominal alpha value set to 0.05 was used to
identify signiﬁcant changes, followed by Benjamini-Hochberg
multiple testing correction in order to reduce the false positive rate. Results (fold change 61.5) were then separated into
signiﬁcant increases or decreases (p < .05), and used in a
cross platform analysis. Some results were veriﬁed with RTPCR described later.

Experimental Metastasis Assay in GUSB Null/NOD/
SCID/MPSVII Mice
We used beta-glucuronidase (GUSB)-deﬁcient NOD/SCID/
mucopolysaccharidosis type VII mice to identify transplanted
human tumor cells at single cell resolution [38] by virtue of
their constitutive GUSB activity. Following tail vein injection of
5 3 105 cells of MCF-7-Mock, MCF-7-COX-2, MCF-7-COX-2Mock, and MCF-7-COX-2-EP4KD cells in 350 ll PBS, mice were
sacriﬁced at 4 weeks (to assess micrometastases) and 6 weeks
(to assess macro-metastases). Each cell inoculum used eight
mice. In another set of mice, we injected MCF-7-COX-2 cells
pretreated with EP4A (5 lM) for 7 days before injection, 0.3%
DMSO in PBS served as vehicle treatment. Excised lungs,
brain, liver, spleen, and kidneys were cut into two halves, one
half frozen in OCT (Sakura Finetek, Torrance, CA) to assess
GUSB by histological analysis. Serial 10 lm-thick frozen sections were ﬁxed in 10% buffered formalin, blocked with
mouse-on-mouse reagent (Vector Laboratories, Burlingame,
CA) and analyzed for GUSB-stained human cells [38]. At least
10 sections were acquired from evenly spaced areas, and the
average number of metastases per organ was calculated.
Other halves of all organs were stained with H&E [5, 18].
To measure cell proliferation in vivo we used Click-iTV EdU
Alexa FluorV 488 Imaging Kit (Invitrogen, Molecular Probes,
Carlsbad, CA). EdU was injected intravenously 12 hours before
sacriﬁce in these mice following manufacturer protocol.
R

Detection of SLC Having ES Cell Associated Markers
Spheroids were subjected to dual immuno-staining for COX-2
(Abcam, Cambridge, MA) and ALDH1A, CD44, OCT-3/4, SOX-2,
C AlphaMed Press 2016
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Tumor Growth and Spontaneous Metastasis in NOD/
SCID/IL2Rc Null Mice
These T, B, and NK cell deﬁcient mice are excellent hosts for
tumor xenografts [39]. In the ﬁrst experiment (named F1),
mice (n 5 4 for each cell line) were randomized as follows:
subcutaneous inocula of either MCF-7-Mock or MCF-7-COX-2
(5 3 105 or 5 3 104) cells suspended in growth factorreduced Matrigel (3.5 mg in 0.5 ml EMEM) were implanted in
both inguinal and axillary mammary regions (i.e., four sites
per mouse) close to the nipples. Thus, the n value of tumors
for each group was 16. Individual mice received the same
tumor line and inoculums dose. Matrigel implants alone
served as the negative control in ﬁve additional mice [40].
Tumor volumes were measured as 0.5 3 a2b, from the
minimum (a) and maximum (b) diameters at 2-day intervals,
as reported previously [5, 18, 35] until sacriﬁce on day 73.
Upon retrieval, the implants were photographed and sliced
into three pieces, for RNA and protein extraction and retransplantation. Excised lungs, livers, spleens, kidneys, and brains
were cut into two pieces, one frozen for immunohistochemical analysis of HLA and another ﬁxed for H&E staining. Lungs were harvested after inﬂation with PBS. At least
three semiserial 10 mm thick sections of these organs from
each animal were stained with mouse antihuman HLA antibody (1:100 dilution, Sigma-Aldrich) to detect tumor cells
[19].

Serial Transplantation of F1 Tumors into Another Set
of Mice (F2)
We named second-generation tumors as F2. Excised F1
tumors were cut into small pieces, one piece subjected to histology. Other pieces were minced and processed in a 50 ml
conical ﬂask with 10-15 ml of tumor-collagenase solution
(Millipore) on a shaker bath (378C) for 2-3 hours to digest
larger fragments. Then 10 ml HBSS/2% FBS (Thermo Fisher
Scientiﬁc, Waltham, MA) was added and cells sieved through
a 40 lm ﬁlter, spun down at 1,000 rpm for 5 minutes. The
cell pellets were washed thrice in an identical manner and
resuspended in 3 ml 0.25% Trypsin for 5 minutes at 378C and
neutralized with 5 ml DMEMF12/10%FBS. Ten-milliliter HBSS
was then added and cells passed sequentially through a 100
lm ﬁlter and 40 lm Nylon Cell Strainer. The elutes were spun
at 1,000 rpm for 5 minutes and cell pellets suspended with
DMEM-F12 (Thermo Fisher Scientiﬁc, Waltham, MA) in diluted
Matrigel as described earlier [18] at two different inocula (5
3 104 and 5 3 103 cells). The rest of the protocol was the
same as in F1. Remaining cells were cultured in DMEMF12/
10% FBS with 500 lg/ml Geneticin for further assays.

Human Tissue Samples
mRNA Expression. To examine the clinical relevance of COX2, EP2, EP4, ALDH1A mRNA expression in breast cancer, we
obtained frozen female human breast tumor (n 5 105) and
control (n 5 20) tissues (adjacent nontumor tissues veriﬁed as
tumor-free) from the Ontario Tumor Bank. Demographic,
tobacco/alcohol habits, ER, PR, and HER-2 status of tumor
and control of tissue donors are summarized in Supporting
Information Table 2. The majority of the patients (>80%, data
not provided) had a history of some unspeciﬁed cancer in the
family. Of the tumor tissues, 76% were ER positive, 62.9% PR
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positive, 20% HER2 positive, and 9.5% triple (ER/PR/HER2)
negative. Tumor samples were classiﬁed in ﬁve stages (0-IV)
with respect to TNM following Canadian Cancer Society
staging.
In Situ Detection of SLC Markers. We conducted immunostaining for COX-2, NANOG, SOX2, ALDH, and CD44 in deparafﬁnised and rehydrated tissue sections as follows. Sections were
sequentially treated with xylene (5 minutes, 3X) followed by
graded ethanol (100%, 90%, 70%, 2 minutes each, 2X) and
washed with tap water followed by PBS (5 minutes, 3X). Background was blocked with Sniper (Biocare Medical, Concord, CA,
10 minutes) and washing with PBS. Sections were then incubated with primary antibodies (1:100 dilutions) for 1h at room
temperature and washed with PBS (5 minutes, 3X). Then they
were treated with appropriate secondary antibodies (1:500
dilutions) for 45 minutes, followed by washing with PBS (5
minutes, 3X). Finally, cell nuclei were stained with DAPI (10
minutes), followed by washes with PBS (5 minutes, 3X).

Survival Analyses
Coded patient survival data were extracted from the Cancer
Genome Atlas (TCGA) clinical information [41]. Patient survival
was calculated as time in months elapsed from the date of
diagnosis until the date of last contact. Kaplan-Meier curves
for overall survival associated with COX-2 and EP4 expression
were conducted in 942 primary breast carcinomas. A cutoff p
value (p < .05) was determined using log-rank test.

Statistical Analysis
Statistical calculations were performed using GraphPad Prism
software version 5 (La Jolla, CA). All parametric data were
analyzed with one-way ANOVA followed by Tukey-Kramer or
Dunnett post-hoc comparisons. Student’s t test was used for
comparing two data sets and Pearson’s coefﬁcient to assess
statistical correlations. Signiﬁcant differences between means
were accepted at p < .05.

RESULTS
In Vitro Studies
Stable COX-2 Over-Expression Induces Breast Cancer SLCs via
EP4-Dependent Pathway. COX-2 has been shown to induce
aggressive phenotypes in multiple cancer types [10–12]. In
order to determine the effects of ectopic COX-2 on breast
cancer cell phenotype, we over-expressed COX-2 in MCF-7
and SKBR-3 cell lines. Following selection these cells
expressed COX-2 mRNA and protein levels similar to MDAMB-231 cells (Supporting Information Fig 1A, 1B). As expected
from our previous work with endogenous COX-2 [16-19]
ectopically expressed COX-2 in MCF-7-COX-2 and SKBR-3-COX2 cells increased migration (Fig. 1A), invasion (Fig. 1B) and
proliferation (Fig. 1C) of both MCF-7-COX-2 and SKBR-3-COX-2
cells. Furthermore, MCF-7-COX-2 cells displayed downregulation of estrogen receptor (Supporting Information Fig.
1C) and up-regulation of VEGF-A/C/D and all EP receptors
(Supporting Information Fig. 1D). Additionally, the COX-2
inhibitor NS398 and EP4 antagonist ONO-AE3-208 signiﬁcantly
inhibited migration, invasion, and proliferation in COX-2 overexpressing cells. (Fig. 1A-1C). The same dosages of drugs did
C AlphaMed Press 2016
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Figure 1. COX-2 over-expression promotes aggressive breast cancer phenotypes: comparison of (A) migration, (B) invasion, and (C) proliferation of Mock and COX-2 over-expressing cells showing enhancement in all phenotypes with COX-2 over-expression. Treatment of
COX-2 high cells with NS398 and EP4A (ONO-AE3-208) reverted all phenotypic changes. (D): Down-regulation of E-Cadherin and upregulation of Vimentin, N-Cadherin, TWIST1, and SNAIL1 mRNAs in both MCF-7-COX-2 and SKBR-3-COX-2 cells indicates epithelialmesenchymal transition. ZEB1 is up-regulated only in MCF-7-COX-2. (E): Images of spheroids of both COX-2 over-expressing cells.
Increase in stem-like cells (SLC) content in both cell lines shown for successive generations are presented as spheroid number (F) and
perimeter (G). Treatments with NS398 and EP4A reduced spheroid formation compared to vehicle-treated cells, images in (H) and quantiﬁed in numbers (I). Scale bar in ﬁgures E and H represents 200 lm. The data represent the means of three biological replicates 6 SEM.
*, p < .05; **, p < .005; ***, p < .0005. All treatments compared with vehicle treatment and all COX-2-over-expressing cells results are
compared with Mock-cells.

not show any effect on migration or proliferation of parental
cells excluding nonspeciﬁc toxicity (Supporting Information
Fig. 2A, 2B). Collectively, these results demonstrate that our
COX-2 over-expression system recapitulated known COX-2
mediated phenomena in breast cancer cells. We next sought
to determine whether COX-2 was associated with increased
markers of SLC.
As EMT is associated with SLCs, we explored the effects of
COX-2 on this phenomenon. In COX-2 over-expressing cells, mRNA
levels of the epithelial marker E-Cadherin (CDH1) was downregulated and mesenchymal markers Vimentin, N-Cadherin,
TWIST1, and SNAIL were up-regulated, indicating induction of EMT
(Fig. 1D); ZEB1 was up-regulated only in MCF-7-COX-2 cells.
As a functional correlate, both COX-2 high cell lines
showed a signiﬁcant increase in both the frequency and size
(growth rate) of spheroids that persisted for successive generations (images in Fig. 1E, quantitation in Fig. 1F, 1G). Furthermore, these effects of COX-2 on spheroid formation were
abrogated when COX-2 overexpressing cells MCF7-COX-2 and
SKBR-3-COX2 cells (Fig. 1H, 1I) and also intrinsically COX2 high
cells Hs578T cells (Supporting Information Fig. 2C, 2D) were
treated with an EP4A or COX-2 inhibitor for 24 hours. HowC AlphaMed Press 2016
V

ever, these treatments had no effect on parental cell lines
(Supporting Information Fig. 2E, 2F). These results suggest
that SLC induction in COX-2 over-expressing cells is dependent
on both COX-2 and EP4 activity.
Expression of stem cell markers in spheroids reﬂects the presence of SLCs. We observed a preferential colocalization of SLC
markers with COX-2 (yellow, shown in inset) in both MCF-7-Mock
and MCF-7-COX-2 spheroids (Fig. 2A), consistent with COX-2
induction of SLC phenotype (quantitative data in Supporting
Information Fig. 3A). Flow cytometry analysis showed, respectively, 7% and 6% increases in ALDH positive cells in MCF-7-COX2 (Fig. 2B) and SKBR-3-COX-2 (Fig. 2C) cell lines compared to
Mock cell lines. Spheroid formation also increased the incidence
of SLC marker (ALDH activity, CD24 and CD44) bearing population
in MCF-7 parental and MCF-7-Mock cells (Supporting Information
Fig. 4A-4C); this increase was less pronounced in MCF-7-COX-2
cells, which already had a high incidence (Supporting Information
Fig. 4D), indicating that COX-2 over-expression on its own
increased SLC marker bearing cells. Interestingly, almost all ALDH
high cells within MCF-7-COX-2 cells were positively gated for
CD241 and CD441 (Fig. 2D ﬁrst two rows), having few or no
CD441CD24- subset (lowest row of Fig. 2D).
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Figure 2. COX-2 over-expression increased SLC contents in breast cancer: (A) preferential colocalization of COX-2 and SLC markers in
MCF-7-COX-2 spheroids compared to Mock (yellow, shown in inset). FACS analysis showed 7 and 6% increase in ALDH positive cell populations in (B) MCF-7-COX-2 and (C) SKBR-3-COX-2 cell lines, compared to Mock cell lines, DEAB staining serving as negative control. (D):
In dual labeled (ALDH-CD44) and (ALDH-CD24) MCF-7-COX-2 cells, more than 95% of ALDH positive cells are positive also for CD44 and
CD24. In triple-labeled cells, all ALDH high cells are also positive for both CD44 and CD24; only a small side population of ALDH high
cells was low in CD24 and high in CD44. Scale bar in ﬁgure (A) represents 50 lm.
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Figure 3. Linking COX-2 and SLCs: mRNA expression in a panel of breast cancer cells showing highest COX-2 expression (A) and spheroid formation efﬁciency (SFE) in COX-2 high cells (B). (C): COX-2 expression increased in all cell line-derived spheroids with substantial
increase demonstrated in COX-2 low T47D cells, and minimal increases in COX-2 high MDA-MB-231 cells. (D) PGE-2 and PGE1OH treatments compared to vehicle treatments increased spheroid formation in T47D, SKBR-3, and MCF-7 cells, shown by spheroid numbers (E)
and sizes (F). Preferential coexpression of SLC markers and COX-2 (yellow) was noted in (G) MCF-7 and (H) T47D spheroids after
PGE1OH treatment. Scale bar in ﬁgure (D) represents 200 lm and in ﬁgures (G, H) 50 lm. All experiments replicated three times. The
data represent the means biological replicates 6 SEM; *, p < .01; **, p < .001; *** p < .0001.
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To further explore the possibility that COX-2 may sustain
SLCs, we screened human breast cancer cell lines representing
luminal (T47D, MCF-7) and basal (SKBR-3, MDA-MB-231,

Hs578T) subtypes for COX-2 (PTGS2) mRNA expression and
tested their spheroid forming efﬁciency (SFE) [5]. Results
showed a parallel between COX-2 mRNA expression (Fig. 3A)

Figure 4.
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and SFE (Fig. 3B), both being highest in MCF-7-COX-2 and
lowest in T47D. Several studies have shown that spheroid culture enriches for SLCs. Hence, we asked if spheroid formation
selects for COX-2 expression in both basal and luminal type
breast cancer cells. COX-2 expression increased in all cell lines
grown as spheroids relative to monolayers, but the most substantial increase was evident in luminal cells (T47D, MCF-7)
having low intrinsic COX-2 expression, and minimal increase
was noted in basal cells (MCF-7-COX-2, MDA-MB-231, Hs578T)
which exhibited high intrinsic COX-2 expression (Fig. 3C).
Given that prostaglandin receptors (EP)s mediate many of
the functions of COX-2, we next investigated the role of EPreceptor activation in SLC induction. We treated COX-2-low
cell lines T47D, MCF-7, and SKBR-3 (which produce very low
PGE2) with exogenous PGE2 (binding to all EP-receptors) and
EP4 agonist PGE1OH (binding selectively to EP4). Both treatments increased spheroid formation nearly to a similar degree
(images shown in Fig. 3D; quantiﬁcation in Fig. 3E, 3F), indicating stimulatory roles of EP receptors in spheroid formation.
Preferential coexpression of COX-2 and SLC markers were
observed in PGE1OH treated MCF-7 (Fig. 3G) and T47D spheroids (Fig. 3H), quantitative data for T47D provided in Supporting Information Fig. 3B. Collectively, these data suggest
that COX-2 induces breast cancer SLCs and that this effect is
primarily EP4-dependent.
Differentially Expressed Genes in MCF-7-COX-2 Cells Identiﬁed with Microarray. Using mRNA micro-array comparing
MCF-7-COX-2 and Mock-transfected cells, restricting our selection to a minimum of 61.5-fold changes with p < .05 (after
False Discovery Rate correction), we selected 21 up-regulated
genes for further validation and few down-regulated genes
(Supporting Information Table 3). Up-regulated genes are
NOTCH1, NOTCH2, AXIN1, WISP1, WNT1, CTNNB1, and RHOU
genes. We further validated change in NOTCH and WNT pathway genes as described later. Although there are more than
50 genes, which were marginally up-regulated in COX-2 high
cells, we selected ALDH1A, CD44, NANOG, SOX2, and POU5F1,
because we observed that these markers were up-regulated
in spheroid forming SLCs as well as in tumors in our syngeneic
COX-2 expressing murine breast cancer model [5]. Other
genes associated with cancer progression (VEGFA and
C1QTNF6 linked with angiogenesis, AMOTL1 and FGFR4 involving migration), and EMT (masenchymal SNAI2, CDH2, PCD19)
was also signiﬁcantly up-regulated. Down-regulated genes
included N1N1 (GSK3beta interacting protein), PTEN (negative
regulator of PI3K), PTGFRN (negative regulator of PGE2 receptor), Cadherin genes (PCDH9, PCDH20). These data further
supports our observations of the SLC and EMT phenotypes
resulting from genetic alterations due to COX-2 overexpression.
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Linking NOTCH and WNT Pathways to COX-2/EP4 Induced
SLC Function in Breast Cancer. Above results combined with
the microarray data led us to hypothesize that COX-2 induces
SLC via EP4 activation followed by stimulation of PKA/PI3K/
AKT/NOTCH/WNT pathways (schematic diagram presented in
Fig. 4A). Both PKA (downstream of EP2/EP4) and PI3K/AKT
(downstream of EP4) inhibit GSK3, a negative regulator of
WNT/b-catenin and NOTCH, to perpetuate cell proliferation.
This hypothesis was also consistent with down-regulation of
NINI and PTEN after COX-2 over-expression. We wanted to
test if EP4 activation induces NOTCH and WNT stem cell pathways known to stimulate SLC.
In order to determine whether COX-2 expression is associated with activation of WNT and NOTCH, we measured the aforementioned genes in MCF-7-COX-2 and SKBR-3-COX-2 (relative to
respective Mock-transfected) cell lines in monolayer cultures
using qRT-PCR. We noted that COX-2 induces a signiﬁcant
increase in NOTCH1 and NOTCH2 but minor changes in NOTCH3,
HES1, and HES6 mRNA expression in MCF-7-COX-2 cells (Fig. 4B),
data for SKBR-3-COX-2 presented in Supporting Information Fig.
5A. MCF-7-COX-2 cells showed signiﬁcantly increased expression
of WNT transcription factors Cyc-D1, AXIN1, and AXIN2 but no
change in c-Myc (Fig. 4B), while SKBR-3-COX-2 cells showed no
change in the expression of WNT genes (Supporting Information
Fig. 5A). These data reveal that COX-2 mediates up-regulation of
a subset of NOTCH and WNT family genes.
As spheroid cultures are enriched for SLCs concomitant
with COX-2 expression, we next compared NOTCH and WNT
associated gene expression in spheroids versus monolayers.
We found that spheroid growth was associated with the stimulation of all NOTCH and WNT family genes in MCF-7-COX-2
cells except c-MYC (Fig. 4C). In SKBR-3-COX-2 cells all WNT
and NOTCH genes were upregulated except NOTCH1 and
NOTCH3 (Supporting Information Fig. 5B).
Next, we treated COX-2-low cell lines T47D and MCF-7
with 10 lM of PGE2 and PGE1OH and measured expression
of NOTCH and WNT pathway genes. In MCF-7 cells, both
treatments effectively increased the expression of all genes
except NOTCH3 and AXIN2 (Fig. 4D). For T47D, both treatments unregulated selective NOTCH and WNT pathway genes
(Supporting Information Fig. 5C). Thus, COX-2/EP4 mediated
SLC induction in human breast cancer cell lines is associated
with an up-regulation of NOTCH and WNT.
Given that EP4 activation leads to the induction of PI3K
and that this kinase promotes NOTCH and WNT signaling, we
next measured NOTCH and WNT genes in MCF-7 and T47D
cells following PGE2 and PGE1OH treatment in the presence
or absence of speciﬁc pathway inhibitors: an irreversible PI3K
inhibitor Wortmannin (WT), a reversible PI3K inhibitor LY204002 (LY), or respective vehicles for 24 hours. Since EP4
activation can also stimulate ERK [21] we also used an irreversible ERK inhibitor U0126. Both WT and LY variably

Figure 4. Linking COX-2 and NOTCH and WNT signaling: (A) Hypothetical scheme showing EP4 induces SLC via WNT/b-catenin and
NOTCH pathways. (B): COX-2 over-expression increased NOTCH1, NOTCH2, Cyc-D1, AXIN1, and AXIN2 expression in MCF-7-COX-2 cells.
(C): Spheroid culture condition stimulated both NOTCH and WNT genes except c-Myc and AXIN1 in MCF-7-COX-2 cells compared to
monolayer cells. (D): PGE-2 and PGE1OH treatments increased both pathway genes except NOTCH3 and AXIN2 in MCF-7. AKT inhibitors
LY and WT signiﬁcantly reduced PGE-2 and PGE1OH induced NOTCH (E) and WNT (F) signaling in MCF-7. WNT inhibitor rhDkk-1 and
NOTCH inhibitor DAPT inhibit PGE-2 and PGE1OH induced spheroid formation of MCF7 (quantiﬁcation in G; image in H) and also in
MCF-7-COX-2 cells (quantiﬁcation in I; image in J). Scale bar in ﬁgures (H and J) represents 100 lm. The data represent means of
triplicates 6 SEM; compared to Mock transfected or vehicle treated cells. *, p < .01; **, p < .001; ***, p < .0001.
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suppressed PGE2 and PGE1OH induced NOTCH-1/2/3, HES1,
and HES6 expression and WNT-responsive genes in MCF-7
cells (Fig. 4E, 4F) and T47D cells (Supporting Information

Fig. 5E, 5F), but U0126 had little or no effect (data not
shown). These data suggest that the EP4-PI3K/AKT axis stimulates NOTCH and WNT during SLC induction.

Figure 5.
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To show the contribution of NOTCH and WNT pathways in
EP4 mediated SLC induction, we used NOTCH and WNT inhibitors DAPT (50 and 100 ng) and rhDkk-1 (5 lM and 10 lM).
Both inhibitors signiﬁcantly reduced PGE2 and PGE1OH stimulated spheroid formation in MCF-7 cells (quantiﬁcation in Fig.
4G; images in Fig. 4H) and in MCF-7-COX-2 cells (quantiﬁcation in Fig. 4I; images in Fig. 4J) in a dose dependent manner.

In Vivo Studies
COX-2 Over-Expression Promotes Lung Colony Formation in NOD/
SCID/GUSB Null Mice via EP4-Dependent Mechanisms We
previously showed that inhibiting COX-2 or EP4 activity
reduced the growth of COX-2 expressing murine C3L5 primary
breast carcinomas and their spontaneous metastases in vivo
[5, 18]. In this study, we injected MCF-7-Mock and MCF-7COX-2 cells into the tail vein of GUSB null/NOD/SCID mice
and euthanized them at 4 and 6 weeks to quantify lung colonies with GUSB staining (red, marking donor cells) and metastases in other organs We selected a minimum of three
subserial coronal sections of lungs in each mouse to represent
the largest surface area to score metastatic foci. For other
organs we scanned a minimum of ﬁve sections of each organ
per mouse. Morphological data are presented in Fig. 5A, 5B.
The incidence of lung-metastasis-bearing mice among the
mice injected with tumor cells and the incidence of metastatic
foci per lung in those bearing metastases are shown in Fig.
5C. Both parameters were signiﬁcantly higher in mice injected
with MCF-7-COX-2 cells, as compared to MCF-7-Mock cells.
Metastatic colonies in the spleen and liver were also recorded
with MCF-7-COX-2 cells (Fig. 5D).
To investigate the contribution of EP4 in lung colonization,
we stably knocked-down EP4 in MCF-7-COX-2 cell line (named
as MCF-7-COX-2-EP4KD, Supporting Information Fig. 6A) or
treated MCF-7-COX-2 cells with EP4A (5 lM) for 7 days in
vitro before tail vein injection. EP4A treatment (morphology
in Fig. 5E) and EP4 knock-down (morphology in Fig. 5F) in
MCF-7-COX-2 cells reduced both the lung colony numbers
(Fig. 5G) and colony sizes (Fig. 5H).
Mammary Site Transplantation of MCF-7-COX-2 Cells Promotes Tumor Growth and Spontaneous Metastasis in NOD/
SCID/IL2Rc Null Mice. Mammary transplants of MCF-7-COX2 cells were carried out in NOD/SCID/IL2R! null mice rather
than NOD/SCID/GUSB null mice because the former strain
lacks functional T/B/NK cells accepting better xenotransplants.
In ﬁrst generation (F1) transplants, tumor takes (incidence)
and growth were signiﬁcantly higher with MCF-7-COX-2 cells
compared to MCF-7-Mock cells at respective inoculum doses
(Fig. 6A). On days 73-75, excised tumors were re-transplanted
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in another set of mice at lower inoculum doses (5 3 104 and
5 3 103 cells), called generation F2. Tumor take with MCF-7COX-2 cells was 100% in both F1 and F2 (Fig. 6B). For MCF-7Mock cells the incidences were 60%-80% in F1 and only 30%
in F2 (Fig. 6B). MCF-7-Mock tumors remained avascular and
grew poorly, whereas MCF-7-COX-2 transplants grew larger
and were vascular (Fig. 6C).
We next sought to determine if spontaneous metastasis
was affected by COX-2 expression. HLA staining for humanderived cells conﬁrmed spontaneous lung metastasis in mice
bearing both F1 and F2 MCF-7-COX-2 tumors (Fig. 6D). Lung
metastases arising from COX-2 and Mock cells were enumerated and data are presented as the number of lung colonies
(>8 cells) and clusters (2-8 cells) in Fig. 6E. Representative
images of clusters (<8 cells) are presented in Supporting
Information Fig. 6B-4G. Even with H&E staining (Fig. 6F), we
identiﬁed spontaneous metastatic colonies in the lungs,
spleen and liver of all MCF-7-COX-2 tumor-bearing mice in F1
(100%), whereas only one mouse bearing MCF-7-Mock tumor
displayed clusters in the spleen and liver (12.5%) and two
mice showed lung colonies (25%).
To determine SLC frequencies within tumors, cell lines
derived from MCF-7-Mock and MCF-7-COX-2 tumors were
named MCF-7-Mock-T and MCF-7-COX-2-T respectively. Both
cell lines showed accelerated ability to form very large spheroids (>60 lm diameter) as early as day 3 (image and quantitation in Supporting Information Fig. 7A-7C), compared to 712 days required by MCF-7 cells to grow spheroids of that
size [19]. We noted a dramatic increase in COX-2-positive cells
in both cell line spheroids, indicating a selection in vivo (Supporting Information Fig. 7D). Double immune-staining for
COX-2 and SLC markers (ALDH1A, CD24, CD44, b-Catenin and
SOX-2) in spheroids revealed higher incidence of cells coexpressing COX-2 with ALDH1A, CD44 and b-Catenin in MCF7-COX-2-T spheroids than in MCF-7-Mock-T spheroids, which
displayed high CD24 and b-Catenin coexpression (quantitative
data not provided).
We next wanted to determine if COX-2 induced phenomena, such as EMT and expression of proangiogenic/lymphangiogenic factors observed in vitro, were recapitulated in the
tumors. We quantiﬁed EP4, VEGF-C/D, LYVE-1, CD31, and ECadherin/Vimentin mRNA with Taqman gene expression assays
in tumors extracted from F1. MCF-7-COX-2 tumors showed
signiﬁcant up-regulation of EP4, angiogenesis and lymphangiogenesis markers VEGF-C/D, LYVE-1/CD31 and masenchymal
marker Vimentin and down-regulation of epithelial marker ECadherin (CDH1) compared to MCF-7-Mock tumors (Supporting Information Fig. 8). We could not retrieve enough tissue
from F2 tumors to extract RNA. These patterns also occurred
at the protein level (Fig. 6G). Angiogenic and lymphangiogenic

Figure 5. COX-2 over-expression promotes the incidence and growth of micrometastases: GUSB staining (marking donor cells, red)
showing pulmonary micro-metastases following intravenous injections of (A) MCF-7-Mock and (B) MCF-7-COX-2 cells at 4 weeks and 6
weeks. H&E staining presented in the bottom panel. (C): Incidence of colony bearing lungs, mean colony numbers and sizes (perimeters)
in mice injected with MCF-7-COX-2 cells are higher compared to mice injected with MCF-7-Mock at both the time points. (D): H&E
staining of liver and spleen conﬁrmed metastatic colonies in mice bearing MCF-7-COX-2. (E): EP4A treatment of MCF-7-COX-2 cells with
ONO-AE3208 (5 lM for 7 days) before injection or (F) EP4 knock-down (KD) in MCF-7-COX-2 cells reduced lung colony formation compared to mock transfected or vehicle treated cells. For both assays, reduction in lung colony numbers and sizes are presented in (G)
and (H) respectively. Scale bar in ﬁgures (A), (B), (E), and (F) in GUSB staining pictures represents 50 lm and H&E staining pictures in
(A), (B), (D), (E), and (F) represents 100 lm. The data represent means (8 mice per condition 3 3 sections per lung. n 5 24) 6 SEM. *,
p < .05; **, p < .005; ***, p < .0005.
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Figure 6. MCF-7-Mock and MCF-7-COX-2 cells transplanted in NOD/SCID/IL-2Rg null mice, 4 mice per dose of cells transplanted at four
points, n 5 16. (A): Tumor growth was evidently high with MCF-7-COX-2 transplants compared to MCF-7-Mock in both F1 (primary
transplants) and F2 (secondary transplants). (B): Tumor take was 100% for MCF-7-COX-2 transplants in both experiments while for Mock
it goes down from 60%-80% in F1 to 20%-30% in F2 transplants. (C): Pictures showing larger tumors with increased vasculature in COX2 transplants compared to Mock. Matrigel implants served as negative control. (D): Spontaneous metastasis to lungs was conﬁrmed by
human HLA staining, quantitation presented in (E), data presented as mean (4 mice per condition X 4 lungs X 3 sections per lung,
n 5 48) 6 SEM. *, p < .05; **, p < .005; ***, p < .0005. (F): MCF-7-COX-2 implants produced secondary metastasis in liver and spleen,
shown by H&E staining. Scale bar in ﬁgures D and F represents 100 lm. (G): Western blot analysis of F1 and F2 tumor lysates (pooled
from 8 tumors per group, triplicate measurements, shown in duplicate) and F1-tumor derived cell lines MCF-7-Mock-T and MCF-7-COX2-T lysates. In F1, VEGF-A, C, D, Vimentin, pAKT and pERK expressions were higher compared to MCF-7-Mock lysates; in contrast
E-Cadherin expression went down. In all F2 tumors expression of all markers increased compared to F1. MCF-7-COX-2-T cell line showed
higher expression of all markers and down-regulation of E-Cadherin compared to MCF-7-Mock-T cells.

proteins (VEGF-C and VEGF-D) and mesenchymal protein
(Vimentin) were up-regulated and epithelial marker ECadherin down-regulated in MCF-7-COX-2 tumors as compared to MCF-7-Mock tumors in both F1 and F2. Similar alterations were also observed in F1 derived tumor cell lines MCF7-Mock-T and MCF-7-COX-2-T (Fig. 6G). Finally, we determined
PI3K/AKT and/or ERK1/2 phosphorylation in all cell lines and
tumor lysates of F1 and F2. Over-expression of COX-2
increased phosphorylation of both AKT and ERK in cell lines
and tumors in all conditions tested. All images are presented
in Fig. 6G and quantiﬁcation presented in Supporting Information Fig. 9.

In Situ Studies
COX-2, EP2, EP4, and SLC Marker Expression Levels in
Primary Human Breast Cancer. We quantiﬁed COX-2 (Fig.
7A), EP2 (Fig. 7B), EP4 (Fig. 7C), ALDH1A (Fig. 7D) mRNA
expression in a panel of human breast cancer (n 5 105) and
adjacent nontumor (n 5 20) tissues. RNA extraction and cDNA
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synthesis were performed as described previously [19]. Data
expressed as delta Ct (lower delta Ct indicate higher expression), revealed signiﬁcantly higher expression of all markers in
tumor than nontumor tissues. The mean of delta Ct values of
three control genes GAPDH, b-actin and RLP5 were used to
normalize mRNA expression. Strong positive correlation is
noted between COX-2/EP4 (Fig. 7E), EP4/ALDH1A (Fig. 7F) and
COX-2/ALDH1A (Fig. 7G) in breast cancer tissues. COX-2 and to
some extent, EP2 and EP4 expression increased with the stage
of cancer. ALDH1A was expressed at all stages, the highest
expression observed in stage IV (Fig. 7H).
In situ immunoﬂuorescence staining of breast cancer tissue sections (n 5 10), revealed colocalization of ALDH, SOX2,
OCT3/4, NANOG, and CD44 in a subpopulation of COX-2 positive cells (Fig. 7I).
Survival analysis was done with data extracted from
human cancer genome atlas [41]. Results revealed that high
expression of COX-2 (Fig. 7J) and EP4 (Fig. 7K) genes was
associated with reduced patient survival.
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Figure 7. Box-and-whisker plot showing over-expression of (A) COX-2, (B) EP2, (C) EP4, and (D) ALDH1A mRNA in primary human
breast tumors (n 5 105), in comparison to nontumor control tissue (n 5 20). A more negative DCt value indicates a higher mRNA
expression level. Strong positive correlation existed between (E) COX-2/EP4, (F) EP4/ALDH1A, and (G) COX-2/ALDH1A in patient population. Data presented as mean of n 5 105 for tumor and n 5 20 for control tissue. (H): COX-2, EP2, EP4, and ALDH1A expression were
the highest in stage IV. (I): Double immune staining of COX-2 and SLC markers in breast tissue sections (yellow) showing co-localization
of ALDH, SOX2, OCT3/4, NANOG, and CD44 with COX-2. In ﬁgure (I), images with NANOG and ALDH scale bar represents 20 lm and in
images with SOX2, OCT3/4, and CD44 scale bar represents 10 lm. Data mining results showing high expression of (J) COX-2 and (K) EP4
is associated with reduced patient survival.; *, p < .05; **, p < .01; ***, p < .005.
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DISCUSSION
In the present study, we demonstrate the stimulatory roles of
COX-2 and EP4 in human breast cancer progression and SLC
induction via PI3K/AKT/NOTCH and WNT pathways, combining
in vitro, in vivo, and in situ approaches. This work supports our
previous studies, wherein we showed SLC stimulatory roles of
COX-2 and EP4 in a murine breast cancer model [5]. The role
of COX-2 in SLC induction has been hypothesized [42] and the
roles of EP4 documented in human breast cancer cells [43].
We reported that COX-2/EP4 mediated induction of an oncogenic microRNA-526b was linked with SLC stimulation [19].
However, the mechanisms underlying COX-2/EP4 mediated SLC
induction in human breast cancer remained unclear. In the
present study, for the ﬁrst time, we identiﬁed the mechanistic
roles of COX-2/EP4 in SLC induction in human breast cancer,
proposing a linear activation of COX-2, EP4, PI3K/AKT leading
to up-regulation/activation of NOTCH and WNT pathways
(Schema presented in Fig. 4A), which are SLC-linked.
Multiple approaches adopted in our study were corroborative in nature. Our ﬁndings of a positive correlation of COX2 expression with spheroid forming ability in genetically disparate human breast cancer cell lines (Fig. 3) suggested that
COX-2 may stimulate SLCs irrespective of breast cancer genotype. This contention was validated by the phenotypic
changes resulting from ectopic COX-2 over-expression in COX2 low HER21/2 cell lines. Our in situ studies of genetically
heterogeneous human breast cancer tissue mRNA, showing a
positive correlation of COX-2 and EP4 with the SLC marker
ALDH reinforces this view. In further support, we noted an
association of immune-stained SLC markers with COX-2 in
breast cancer cells in situ.
Several studies including ours have reported the contribution of EP4 receptor on tumor cells [5, 18, 42] as well a host
cells such as NK cells [44] and macrophages [5] in murine
breast cancer progression. Activation of PKA pathway shared
by EP2 and EP4 [22] was identiﬁed as one of the mechanisms
in COX-2 mediated SLC stimulation [19]. EP4 activation can
also stimulate ERK [45] and PI3K/AKT [46] pathways, respectively, promoting PGE-2 dependent cell survival [46] and
migration [47]. In our murine C3L5 breast cancer model, therapy with EP4 antagonists inhibited tumor growth and metastasis to lymph nodes and the lungs, and residual tumors
exhibited reduced AKT phosphorylation, indicating EP4 inactivation [5, 18]. Furthermore, EP4A therapy exhibited a distinct
SLC-reductive effect, as noted from the reduction of multiple
SLC marker bearing cells in residual tumors [5]. In the present
study, the roles of EP4 receptor in COX-2 mediated aggressive
functions and SLC induction in human breast cancer were
demonstrated with multiple approaches: (a) stimulation of all
aggressive breast cancer functions in vitro could be blocked
with COX-2 inhibitors as well as EP4 antagonists. (b) Pretreatment of MCF-7-COX-2 cells with an EP4 antagonist or EP4
knock-down of the cells reduced their lung colony forming
ability in vivo. (c) EP4 activation in vivo was indicated by
increased AKT and ERK phosphorylation in serial xenotransplants. (d) EP4 activation in multiple COX-2 low cells with an
EP4 agonist promoted SLC phenotype as shown by increased
spheroid forming efﬁciency and the incidence of SLC-marker
bearing cells. (e) Concomitantly there was up-regulation of
certain genes in NOTCH and WNT family, which could be
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blocked by inhibiting the PI3K/AKT pathway, unique to EP4
activation, not shared by EP2 [22]. However, our studies did
not exclude the roles of cAMP-PKA pathways shared by EP2
and EP4. Indeed, PGE-2 mediated SLC stimulation noted in
our study could be in part due to EP2 activation. In our COX-2
expressing murine breast cancer model we have excluded the
role of EP1 in tumor growth and metastasis [18]. (f) EP4
mediated SLC induction was shown to be dependent on
NOTCH and WNT activation. (g) A positive association of EP4
mRNA expression with SLC marker ALDH1A was noted in
human primary breast cancer tissues, and high EP4 expression
was associated with reduced survival.
Activation of NOTCH [48] and WNT [49] pathways has been
shown for cell renewal and cell fate determination in human
embryonic stem cells. Both NOTCH [26, 27] and WNT [28, 29]
pathways were reported to be activated in breast cancer, promoting metastatic phenotype. Furthermore a small molecule
inhibitor of WNT/b catenin was shown to be SLC-reductive in
breast cancer cells [50]. PGE-2, the major bioactive product of
the COX-2 cascade can protect embryonic stem cells [51] and
activate components of the WNT signaling system [31]. In this
study, we observed an up-regulation of NOTCH and WNT signaling genes following ectopic COX-2 expression or treating COX-2
low T47D and MCF-7 cells with the nonselective EP ligand PGE-2
or a selective EP4 agonist PGE1OH. These treatments also promoted spheroid formation. Furthermore, PGE-2 and PGE1OH
mediated up-regulation of NOTCH and WNT was blocked with
selective P13K-AKT inhibitors. NOTCH and WNT inhibitors could
also block COX-2/EP4 induced spheroid formation. Thus, for the
ﬁrst time we have shown that EP4 receptor activity, via PI3K/
AKT signaling followed by NOTCH/WNT up-regulation/activation
plays a role in COX-2 mediated SLC induction.
Conventional tumor growth assays using histology and/or
whole animal imaging do not permit the single cell resolution
that we uncovered with the GUSB-null mouse model. COX-2
over-expressing cells injected intravenously in these mice formed
micrometastasis in the lungs at 4 weeks, progressing to macrometastases by 6 weeks, at which time the mice showed multiorgan
metastases. In contrast, the Mock cells were identiﬁed either as
single cell or small clusters in the lungs, which never progressed
to micro-metastases even at 6 weeks, indicating that COX-2 overexpression may promote growth of dormant cells. This view was
supported by the fact that few or no EdU positive cells were
noted in the lungs of MCF-7-Mock injected mice, whereas colonies in MCF-7-COX-2 injected mice revealed high incidence of
EdU positive cells (Supporting Information Fig. 10).
Demonstration of SLC properties by single cell transplantation is hard in the case of solid tumors because of cellular heterogeneity, in which case SLC phenotype in vitro, combined
with tumorigenicity with small cell numbers in serial transplants expressing SLC-associated markers have been useful [3,
36]. In the present study, we observed that COX-2 over-expression leads to an enrichment of ALDHhighCD441CD241 cells in
association with increased spheroid forming efﬁciency, we
could not however identify a subset which is
ALDHhighCD441CD242. It is possible that COX-2 induced SLC
phenotype does not necessarily deplete CD24 positive cells. In
spheroid derived cells ALDH, CD44, and CD24 positive cells was
more evident for COX-2 low MCF-7, than MCF-7-COX-2 cells,
likely because spheroid formation leads to increased COX-2
expression in COX-2 low cell lines (Fig. 3A, 3B). COX-2
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association with SLC in vivo was further demonstrated by serial
transplantation. We observed aggressive growth of implants at
the mammary sites in IL2Rc null mice with 5 3 104 MCF-7COX-2 cells in the ﬁrst generation and only 5 3 103 MCF-7COX-2 tumor dissociated cells in the second generation, indicating the role of COX-2 in SLC selection in vivo. This inference
was further supported by enrichment of SLC-marker bearing
cells co-expressing COX-2 in tumor-derived spheroids.
Metastatic tumor cells can survive at secondary sites in
the body circumventing a need for growth or progression, a
property called tumor dormancy [52]. In the present study,
using HLA marker, we observed spontaneous lung colonies
and clusters of MCF-7-COX-2 in cells seeding from mammary
site transplants in IL2Rc null mice. In MCF-7-Mock transplants
we never found spontaneous lung colonies, whereas occasional single cells were noted indicating metastatic cells that
remained dormant. These ﬁndings were also reproduced in
second-generation transplants, reinforcing the role of COX-2 in
abrogation of tumor dormancy.
Signiﬁcant up-regulation of the VEGF family members and
angiogenesis and lymphangiogenesis markers in MCF-7-COX-2
derived tumors relative to MCF-7-Mock tumors further support the stimulatory roles of COX-2 in angiogenesis and lymphangiogenesis, already demonstrated in our murine breast
cancer model [5, 18]. This also applied to increased AKT and
ERK activation in MCF-7-COX-2 tumors in vivo, as demonstrated in the murine breast cancer model [5, 18] reinforcing
the role of EP4 activity in COX-2 mediated tumor progression.
We suggest that COX-2 and EP4 are both partners in SLC
induction in breast cancer. This suggestion is supported by (a)
a reduction in spheroid formation with COX-2 inhibition; (b)
EP4 antagonism or gene knock-down reducing lung colonies
in vivo; (c) a strongly positive correlation of COX-2/EP4 mRNA
with breast cancer stem cell marker ALDH1A in tumor tissues;
(d) preferential colocalization of immunostained SLC markers
with COX-2 in breast tumor tissues.
Our studies in the human, for the ﬁrst time demonstrate
the role of EP4, and EP4 mediated signaling pathways in COX2 mediated human breast cancer progression including SLC
stimulation. While COX-2 inhibitors have demonstrated proven
chemo-preventive and therapeutic effects in numerous
epithelial-derived cancers [13] cardiovascular side effects of
COX-2 inhibitors [23] resulting from inhibition of cardioprotective prostanoids such as PGI2 [25] demonstrate the
need for alternate safe targets downstream of COX-2. We suggest that EP4 exquisitely meets this need. We have already
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